Inadequate immune responses force Merck to abandon COVID-19 vaccines


Merck, one of the world's most storied vaccine makers, is abandoning the development of its two COVID-19 vaccines after initial trials resulted in inadequate immune responses, Stat News reports. Both vaccines produced lower levels of coronavirus antibodies than have been found in the blood of individuals who recovered from natural COVID-19 infections. For reference, the Pfizer-BioNTech and Moderna vaccines produced antibody levels several times higher than natural infections.
The unsuccessful trials are disappointing in large part because both Merck vaccines would have required just one dose, writes Stat. One of the candidates, which uses the same virus as the one in Merck's successful Ebola vaccine, was being developed in partnership with the International AIDS Vaccine Initiative, which has said it will try to determine if using an oral or intranasal administration route will work better than the current intramuscular injection. It's unclear if Merck will continue to collaborate — IAVI's president Mark Feinberg told Stat he hopes they do — because the pharmaceutical company has suggested it will now turn its focus to developing COVID-19 therapeutics.
As Stat notes, the results show just how difficult vaccine development can be, especially in such a short amount of time, making the rapid success of the Pfizer-BioNTech and Moderna shots seem all the more remarkable. Read more at Stat News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Cytomegalovirus can cause permanent birth defects
The Explainer The virus can show no symptoms in adults
-
Summer in Seattle: Outdoor dining like nowhere else
Feature Featuring a patio with a waterfront view, a beer garden, and more
-
Ari Aster revisits the pandemic, Adam Sandler tees off again and Lamb Chop gets an origin story in July movies
the week recommends The month's film releases include 'Eddington,' 'Happy Gilmore 2' and 'Shari & Lamb Chop'
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths